medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2021, Number 12

<< Back Next >>

Ginecol Obstet Mex 2021; 89 (12)

Adult granulosa cell tumor

López-González E, Sillero-Castillo A, Escribano-Cobalea M

Language: Spanish
References: 15
Page: 1002-1008
PDF size: 199.95 Kb.


ABSTRACT

Background: Systemic lupus erythematosus (SLE) is a chronic, multisystemic disease of unknown etiology, whose clinical manifestations are heterogeneous. Pericardial involvement is the most common cardiac complication; however, the development of cardiac tamponade is rare, and even more so in pregnant patients presenting with SLE.
Objective: To present the clinical characteristics, diagnosis, treatment, and evolu- tion of cardiac tamponade in a pregnant patient that presents with systemic lupus erythematosus.
Clinical case: A 24-year-old patient, who is 27.5 weeks pregnant, presenting with anasarca, dyspnea that evolved to orthopnea and stabbing chest pain for three weeks. Her chest X-ray showed cardiomegaly grade II, congestive lung fields and pleural effusion at the level of cardiophrenic sinuses. The echocardiogram found a 500 mL pericardial effusion with evidence of cardiac tamponade. Progressive deterioration with compromised lung capacity, and the appearance of acute renal failure with progressive increases in creatinine; showing hemodynamic instability characterized by paradoxical pulse and hypotension. With positive Antinuclear Antibodies (ANA) and proteinuria, renal biopsy reports histopathological patterns corresponding to lupus nephritis, treated with steroid pulses and intravenous cyclophosphamide in a risk-benefit assessment, with subsequent satisfactory maternal-fetal evolution.
Conclusion: Cardiac tamponade is not common in patients with SLE, and it is even rarer as the initial manifestation, even more so during pregnancy. It is a clinical emergency and requires multidisciplinary management since pregnancy in a patient with SLE implies an increased risk of systemic complications.


REFERENCES

  1. Young RH. Sex cordo-stromal tumors of the ovary and testis: Their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18: 81.https://doi. org/10.1038/modpathol.3800311

  2. Chen VW, Ruiz B, Killeen JL, Cote TR, et al. Pathology and classification of ovarian tumors. Cancer 2003; 97 (10): 2631-264. doi: 10.1002/cncr.11345

  3. Iqbal A, Novodvorsky P, Lubina-Solomon A, Kew FM, Webster J. Juvenile granulosa cell tumor of the ovary presenting with hyperprolactinaemic amenorrhoea and galactorrhoea. Endocrinol Diabetes Metab Case Rep 2016; 2016 (6). https://doi.org/10.1530/EDM-16-0006

  4. Babarovic E, Franin I, Klaric M. Adult granulosa cell tumors of the ovary: A retrospective study of 36 FIGO stage I cases with emphasis on prognostic pathohistological features. Analytical Cellular Pathology 2018; 2018. doi: 10.1155/2018/9148124

  5. Berek JS, Hacker NF. Nonepithelian ovarian and fallopian tube cancers. In practical Gynecologic Oncology. Philadelphia 2000; 539. https://doctorlib.info/gynecology/bereknovak- gynecology/37.html

  6. Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004; 25: 431-38. http://europepmc.org/abstract/MED/2752440

  7. Bjorkholm E, Silfversward C. Prognostic factors in granulosa- cell tumors. Gynecol Oncol 1981; 11 (3): 261-74. doi: 10.1155/2019/2912361

  8. Malmstrom H, Hogberg T, Risberg B, Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 2009; 52 (1): 50-5. doi: 10.1155/2019/2912361

  9. Wang D, Cao D, Jia C, Huang H, Yang J, Wu M, et al. Analysis of oncologic and reproductive out-comes after fertilitysparing surgery in apparent stage I adult ovarian granulosa cell tumors. Gynecol Oncol 2018; 151 (2): 275-81. https:// doi.org/10.1016/j.ygyno.2018.09.004

  10. Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P, et al. Nonepithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (4): 1-18. doi:10.1093/annonc/mdy001

  11. Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent). Cochrane Database Syst Rev 2014; v4: CD006912. doi: 10.1002/14651858.CD006912

  12. Iavazzo C, Gkegkes ID, Vrachnis N. Fertility sparing management and pregnancy in patients with granulosa cell tumour of the ovaries. J Obstet Gynaecol 2015; 35 (4): 331-5. doi: 10.3109/01443615.2014.968107

  13. Hines JF, Khalifa MA, Moore JL, Fine KP, Lage JM, Barnes WA. Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the litera ture. Gynecol Oncol 1996; 60 (3): 484-8. doi:10.1186/1477- 7800-1-4

  14. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes in the treatment of cord sex-stromal ovarian tumors. J Clin Oncol 2005; 97: 489-96. doi:10.1007/s00595-012-0198-5

  15. C.H. Mom, M.J. Engelen, P.H. Willemse, J.A. Gietema, K.A. Ten Hoor, E.G. de vries. Granulosa cell tumors of ovary: The clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 2007; 105: 365-72. https:// doi.org/10.1016/j.ygyno.2006.12.034




2020     |     www.medigraphic.com